With our leading COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum), we expect to commercialize one of the first protein-based COVID-19 vaccines globally, enabling us to potentially help address the global shortage of COVID-19 vaccines.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility